Destiny Pharma : Directorate Change

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Directorate change

Brighton, United Kingdom - 15 November 2021- Destiny Pharma plc (AIM: DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that after almost 25 years supporting the Company, Peter Morgan a Non-Executive Director, has decided to step down from the Board with effect from 31 March 2022. A search for a replacement is underway.

Nick Rodgers, Chairman of Destiny Pharma, commented:

"On behalf of Destiny Pharma, I would like to thank Peter for his considerable contribution to the Company throughout its development as a private company and the transition onto the AIM market. Destiny Pharma is now in a very exciting position to deliver significant value with two late-stage clinical programmes targeting infection prevention that have delivered strong Phase 2 clinical data and are both heading towards Phase 3 clinical studies."

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark / Hollie Vile / Manel Mateus

[phone]

[e-mail]

finnCap Ltd(Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners(Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficileinfection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com